Post-earnings recap
Reported
Mon, Mar 3, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Amicus Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising nearly 2%. The company did not provide revenue figures or future guidance, but management's comments about pipeline progress suggest they are focused on long-term growth. Investors may find reassurance in the company's commitment to developing treatments for rare diseases.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | +36.10% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a cautious optimism about the future. They noted the importance of their ongoing clinical trials and research efforts.
Management highlighted ongoing progress in their pipeline.
They emphasized their commitment to advancing treatments for rare diseases.